Auditory monitoring in childhood cancer
an integrative review
DOI:
https://doi.org/10.23925/2176-2724.2025v37i1e68967Keywords:
Ototoxicity, Hearing Disorders, Antineoplastic Protocols, Child, AdolescentAbstract
Introduction: Chemotherapy drugs are widely used to treat neoplasms and can lead to ototoxicity, damaging auditory cells and causing hearing loss. That is why some groups suggest hearing monitoring protocols to identify any alterations at an early stage. Aim: To identify auditory monitoring routines implemented at national and international level. Methods: Integrative literature review to synthesize results of independent studies about auditory monitoring in children and adolescents diagnosed with cancer. PubMed/Medline, EMBASE and Virtual Health Library databases were searched with terms from Emtree and Medical Subject Headings metadata systems. Results: 1504 articles were found, of which 11 were appraised. Evoked Otoacoustic Emissions were frequently cited and most of the studies performed monitoring at the beginning and throughout treatment to identify ototoxicity. Conclusions: National and international auditory monitoring practices vary on procedures and frequency between assessments.
Downloads
Metrics
No metrics found.
References
Spironello RA, Silva-Comar FMS, Cardia GFE, Janeiro V, Pedroso RB, Cuman RKN. Mortalidade infantil por câncer no Brasil. Saúde Pesqui. (Online). 2020;13(1).
Feliciano SVM, Santos MO, Pombo-de-Oliveira MS. Incidência e Mortalidade por Câncer entre Crianças e Adolescentes: uma Revisão Narrativa. Rev. Bras. Cancerol. (Online). 2018; 64(3): p. 389–96.
Van As JW, Van den Berg H, Van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016; 2016(8): CD010181.
Patatt FSA, Gonçalves LF, Paiva KM, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol. 2022; 88(1):130-40.
Lopes NB, Silva LAF, Samelli AG, Matas CG. Effects of chemotherapy on the auditory system of children with cancer: a systematic literature review. Rev CEFAC. 2020; 22(2): e13919.
Lester GM, Wilson WJ, Timmer BHB, Ladwa RM. Audiological ototoxicity monitoring guidelines: a review of current evidence and appraisal of quality using the AGREE II tool. Int J Audiol. 2023; 7:1-6.
Konrad-Martin D, Polaski R, DeBacker JR, Theodoroff SM, Garinis A, Lacey C et al. Audiologists’ perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey. J Cancer Surviv. 2023;17(1): 69-81.
de Andrade V, Khoza-Shangase K, Hajat F. Perceptions of oncologists at two state hospitals in Gauteng regarding the ototoxic effects of cancer chemotherapy: A pilot study. Afr J Pharmacy Pharmacol. 2009; 3: 307–18.
Costa JC, Buss CH. Análise de prontuários de pacientes oncológicos quanto ao monitoramento auditivo. Rev CEFAC. 2009;11(2): 323–30.
Cronin MA, George E. The Why and How of the Integrative Review. Organ. Res. Methods, 2023; 26(1): 168-92.
Vosgrau JS, Silva LAF, Filho VO, Matas CG. A longitudinal study of the peripheral and central auditory pathways in individuals with acute lymphoid leukemia. Clinics (Sao Paulo). 2023; 78:100234.
Pecora Liberman PH, Schultz C, Goffi-Gómez MVS, Antoneli CB, Chojniak MM, Novaes PE. Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. Clin Transl Oncol. 2011; 13(5): 348-52.
Caldas ÉA, Brito LMO, Caldas PA, Rocha SCM, Ferreira Filho ED, Chein MB da C. Caracterização audiológica de crianças em tratamento oncológico. Audiol, Commun Res. 2015; 20(2):104–09.
Toral-Martiñón R, Poblano A, Collado-Corona MA, González R. Efectos del cisplatino en la función auditiva en niños con cáncer. Evaluación por emisiones otoacústica. Gac Méd Méx. 2003;139(6).
Bhagat SP, Bass JK, White ST, Wilson MW, Wu J et al. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol. 2010;74(10):1156-63.
Bhagat S, Bass J, Qaddoumi I, Brennan R, Wilson MW, Wu J, et al. Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy. Audiol Neurootol. 2013;18(2):71-82.
Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Ear Hear. 2008; 29(6): 830-7.
Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131-6.
Toral-Martiñón R, Shkurovich-Bialik P, Collado-Corona MA, Mora-Magaña I, Goldgrub-Listopad S, Shkurovich-Zaslavsky M. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch Med Res. 2003; 34(3): 205-8.
Waissbluth S, Del Valle Á, Chuang A, Becker A. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol. 2018; 111: 174-9.
Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G. et al. Audiological Monitoring in Children Treated with Platinum Chemotherapy. Audiol Neurootol. 2016; 21(4): 203-11.
Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001; 59(1): 47-57.
Al-Noury K. Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin. Laryngoscope. 2011;121(5):1081-4.
Sanfins MD, Hein TAD, Ubiali T, Colella-Santos MF. Emissões Otoacústicas Transientes e por Produto de Distorção. In: Menezes PL, Sanfins MD, Capra D, Andrade KCL, Frizzo ACF (orgs). Manual de Eletrofisiologia e Eletroacústica: um guia para clínicos. Ribeirão Preto: BookToy; 2022. p. 69-82.
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R et al.. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019; 20(1): e29-e41.
American Academy of Audiology. Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. 2009. Disponível em: https://audiology-web.s3.amazonaws.com/migrated/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf
American Speech-Language Hearing Association. Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy. 1994. Disponível em: https://www.asha.org/policy/gl1994-00003/
Khoza-Shangase, K.; Masondo, N. What Are the Current Audiological Practices for Ototoxicity Assessment and Management in the South African Healthcare Context? Int. J. Environ. Res. Public Health 2020; 17: 2613.
Fernandez KA, Garinis A, Knight K, Konrad-Martin D, Morata T, Poling GL et al. What’s New in Ototoxicity Management?. Perspect ASHA Spec Interest Groups, 2024; 9(1): 113-23.
Moore B, Sheets G, Doss J, Umrigar A, Norman M, Fang Z et al. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment. Am J Audiol. 2023; 32(3): 657-64.
Phelan M, Hayashi SS, Sauerburger K, Henry J, Wu N, Hayashi RJ. Prevalence of hearing screening failures in low-risk childhood cancer survivors. Pediatr Blood Cancer. 2022; 69(2): e29437.
Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorrinolaringol. 2020; 138: 110401.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Camila Franciozi, Viviann Magalhães Silva Borges, Letícia Gregory, Paulo Ricardo Gazzola, Lauro José Gregianin, Pricila Sleifer
This work is licensed under a Creative Commons Attribution 4.0 International License.
